AGENUS INC Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value
AGENUS INC (AGEN) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value of $3.01 per share for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-07.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue · last filed 2026-08-07
- AGENUS INC share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2026-03-31 was $2.43, a 6.90% decline year-over-year.
- AGENUS INC share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2025-03-31 was $2.61, a 70.41% decline year-over-year.
- AGENUS INC share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2024-03-31 was $8.82, a 71.18% decline year-over-year.
- AGENUS INC share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2023-03-31 was $30.60, a 1590.61% increase year-over-year.
- AGENUS INC share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2025 was $3.03, a 71.81% decline from fiscal 2024.
- AGENUS INC share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2024 was $10.75, a 61.88% decline from fiscal 2023.
- AGENUS INC share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2023 was $28.20, a 19.43% decline from fiscal 2022.
- AGENUS INC share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2022 was $35.00, a 1145.55% increase from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 3 month as first filed | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 6 month as first filed | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 9 month as first filed | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 12 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $3.01 10-Q · filed 2026-08-07 | |||||||
| 2026-03-31 | $2.43 10-Q · filed 2026-05-11 | |||||||
| 2025-12-31 | $3.03 10-K · filed 2026-03-16 | |||||||
| 2025-09-30 | $2.98 10-Q · filed 2025-11-10 | |||||||
| 2025-06-30 | $2.90 10-Q · filed 2026-08-07 | |||||||
| 2025-03-31 | $2.61 10-Q · filed 2026-05-11 | |||||||
| 2024-12-31 | $10.75 10-K · filed 2026-03-16 | |||||||
| 2024-09-30 | $11.45 10-Q · filed 2025-11-10 | |||||||
| 2024-06-30 | $11.53 10-Q · filed 2025-08-11 | |||||||
| 2024-03-31 | $8.82 10-Q · filed 2025-05-12 | |||||||
| 2023-12-31 | $28.20 10-K · filed 2026-03-16 | $1.41 10-K · filed 2024-03-14 | ||||||
| 2023-09-30 | $28.80 10-Q · filed 2024-11-12 | $1.44 10-Q · filed 2023-11-09 | ||||||
| 2023-06-30 | $29.80 10-Q · filed 2024-08-08 | $1.49 10-Q · filed 2023-08-08 | ||||||
| 2023-03-31 | $30.60 10-Q · filed 2024-05-07 | $1.53 10-Q · filed 2023-05-09 | ||||||
| 2022-12-31 | $35.00 10-K · filed 2025-03-17 | $1.75 10-K · filed 2023-03-16 | ||||||
| 2022-09-30 | $1.77 10-Q · filed 2023-11-09 | |||||||
| 2022-06-30 | $1.76 10-Q · filed 2023-08-08 | |||||||
| 2022-03-31 | $1.81 10-Q · filed 2023-05-09 | |||||||
| 2021-12-31 | $2.81 10-K · filed 2024-03-14 | |||||||
| 2021-09-30 | $2.83 10-Q · filed 2022-11-08 | |||||||
| 2021-06-30 | $1.99 10-Q · filed 2022-08-09 | |||||||
| 2021-03-31 | $1.49 10-Q · filed 2022-05-10 | |||||||
| 2020-12-31 | $2.04 10-K · filed 2023-03-16 | |||||||
| 2020-09-30 | $1.51 10-Q · filed 2021-11-09 | |||||||
| 2020-06-30 | $1.46 10-Q · filed 2021-08-09 | |||||||
| 2020-03-31 | $1.39 10-Q · filed 2021-05-07 | |||||||
| 2019-12-31 | $1.77 10-K · filed 2022-03-01 | |||||||
| 2019-09-30 | $1.61 10-Q · filed 2020-11-09 | |||||||
| 2019-06-30 | $1.83 10-Q · filed 2020-08-10 | |||||||
| 2019-03-31 | $1.58 10-Q · filed 2020-05-11 | |||||||
| 2018-12-31 | $1.23 10-K · filed 2021-03-16 | |||||||
| 2018-09-30 | $1.28 10-Q · filed 2019-11-07 | |||||||
| 2018-06-30 | $1.29 10-Q · filed 2019-08-09 | |||||||
| 2018-03-31 | $2.14 10-Q · filed 2019-05-10 | |||||||
| 2017-12-31 | $1.90 10-Q · filed 2018-05-10 | $1.97 10-K · filed 2020-03-16 | ||||||
| 2017-09-30 | $1.96 10-Q · filed 2018-11-07 | |||||||
| 2017-06-30 | $1.94 10-Q · filed 2018-08-09 | |||||||
| 2017-03-31 | $1.90 10-Q · filed 2017-05-04 | |||||||
| 2016-12-31 | $4.65 10-K · filed 2019-03-18 | |||||||
| 2016-09-30 | $2.38 10-Q · filed 2017-11-07 | |||||||
| 2016-06-30 | $1.83 10-Q · filed 2017-08-07 | $1.89 10-Q · filed 2016-08-04 | ||||||
| 2016-03-31 | $1.83 10-Q · filed 2017-05-04 | |||||||
| 2015-12-31 | $3.55 10-K · filed 2018-03-16 | |||||||
| 2015-09-30 | $3.85 10-Q · filed 2016-11-09 | |||||||
| 2015-06-30 | $3.59 10-Q · filed 2016-08-04 | |||||||
| 2015-03-31 | $3.21 10-Q · filed 2016-05-09 | |||||||
| 2014-12-31 | $1.87 10-K · filed 2017-03-16 | |||||||
| 2014-09-30 | $1.85 10-Q · filed 2015-11-04 | |||||||
| 2014-06-30 | $1.82 10-Q · filed 2015-08-03 | |||||||
| 2014-03-31 | $2.54 10-Q · filed 2015-05-01 | |||||||
| 2013-12-31 | $2.42 10-K · filed 2016-03-15 | |||||||
| 2013-09-30 | $2.49 10-Q · filed 2014-10-31 | |||||||
| 2013-06-30 | $2.64 10-Q · filed 2014-08-01 | |||||||
| 2013-03-31 | $2.88 10-Q · filed 2014-05-09 | |||||||
| 2012-12-31 | $3.94 10-K · filed 2015-03-16 | |||||||
| 2012-09-30 | $3.94 10-Q · filed 2013-11-08 | |||||||
| 2012-06-30 | $3.95 10-Q · filed 2013-08-09 | |||||||
| 2012-03-31 | $2.72 10-Q · filed 2013-05-10 | |||||||
| 2011-12-31 | $3.61 10-K · filed 2014-03-07 | |||||||
| 2011-09-30 | $3.52 10-Q · filed 2012-11-07 | |||||||
| 2011-06-30 | $4.62 10-Q · filed 2012-08-08 | |||||||
| 2010-12-31 | $3.66 10-K · filed 2013-03-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |